Evaluation of the effects of atorvastatin on the treatment of secondary pulmonary hypertension due to chronic obstructive pulmonary diseases: A randomized controlled trial

Iranian Red Crescent Medical Journal

Volumn 15, Issue 8, 2013, Pages 649-654

  Moosavi, Seyed Ali Javad ^a   Raji, Hanieh ^b   Faghankhani, Masoomeh ^a   Yazdani, Rostam ^c   Esmaeili, Mansour ^d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Department of Cardiology Iranshar Hospital   (Iran)

Author keywords

Chronic obstructive pulmonary diseases (COPD); Hypertension; Pulmonary; Statin

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN; PLACEBO;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEART OUTPUT; HEART VENTRICLE SIZE; HUMAN; MALE; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; WALKING;

EID: 84885699639     PISSN: 20741804     EISSN: None     Source Type: Journal    
DOI: 10.5812/ircmj.8267     Document Type: Article

References (22)

1. Janda S, Park K, Fitz Gerald JM, Etminan M, Swiston J. Statins in COPD: a systematic review. Chest. 2009;136(3):734-43.
2. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574-80.
3. Lee JH, Lee DS, Kim EK, Choe KH, Oh YM, Shim TS, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med. 2005;172(8):987-93.
4. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Cool C, Wood K, Tuder RM, et al. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2006;291(4):L668-76.
5. Girgis RE, Li D, Zhan X, Garcia JG, Tuder RM, Hassoun PM, et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol. 2003;285(3):H938-45.
6. Newman JH, Fanburg BL, Archer SL, Badesch DB, Barst RJ, Garcia JG, et al. Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. Circulation. 2004;109(24):2947-52.
7. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering-are they clinically relevant? European heart journal. 2003;24(3):225-48.
8. Young RP, Hopkins R, Eaton TE. Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev. 2009;18(114):222-32.
9. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol. 2006;6(5):358-70.
10. Fouty BW, Rodman DM. Mevastatin can cause G1 arrest and induce apoptosis in pulmonary artery smooth muscle cells through a p27Kip1-independent pathway. Circ Res. 2003;92(5):501-9.
11. Kao PN. Simvastatin treatment of pulmonary hypertension: an observational case series. Chest. 2005;127(4):1446-52.
12. Murata T, Kinoshita K, Hori M, Kuwahara M, Tsubone H, Karaki H, et al. Statin protects endothelial nitric oxide synthase activity in hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2005;25(11):2335-42.
13. Li M, Liu Y, Dutt P, Fanburg BL, Toksoz D. Inhibition of serotonin-induced mitogenesis, migration, and ERK MAPK nuclear translocation in vascular smooth muscle cells by atorvastatin. Am J Physiol Lung Cell Mol Physiol. 2007;293(2):L463-71.
14. Lee TM, Chen CC, Shen HN, Chang NC. Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin Sci (Lond). 2009;116(6):497-505.
15. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932-46.
16. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):40S-47S.
17. Wilkins MartinR, Ali Omar, Bradlow William, Wharton John, Taegtmeyer Anne, Rhodes ChristopherJ, et al. Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med. 2010;181(10):1106-13.
18. Kaczmarek P, Sladek K, Skucha W, Rzeszutko M, Iwaniec T, Dziedzina S, et al. The influence of simvastatin on selected inflammatory markers in patients with chronic obstructive pulmonary disease. Pol Arch Med Wewn. 2010;120(1-2):11-7.
19. Blamoun AI, Batty GN, DeBari VA, Rashid AO, Sheikh M, Khan MA. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract. 2008;62(9):1373-8.
20. Soyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J. 2007;29(2):279-83.
21. van Gestel YR, Hoeks SE, Sin DD, Simsek C, Welten GM, Schouten O, et al. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol. 2008;102(2):192-6.
22. Reed RM, Iacono A, DeFilippis A, Jones S, Eberlein M, Lechtzin N, et al. Statin therapy is associated with decreased pulmonary vascular pressures in severe COPD. COPD. 2011;8(2):96-102.